This sub-analysis of the ODYSSEY COMBO II study compared the effects of alirocumab, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in high cardiovascular risk patients with or without diabetes mellitus (DM) receiving maximally tolerated statin therapy.
| INTRODUCTION
Diabetes mellitus (DM) is associated with an atherogenic lipid profile, typically characterized by elevated levels of plasma triglycerides (TGs) and reduced concentrations of high-density cholesterol (HDL-C). 1 Individuals with diabetes mellitus (DM) are considered to be at high risk of atherosclerotic cardiovascular disease (ASCVD), and guidelines recommend that such patients receive lipid-lowering treatment to reduce levels of low-density lipoprotein cholesterol (LDL-C). [2] [3] [4] In addition, levels of non-high-density lipoprotein cholesterol (non-HDL-C) more closely align with cardiovascular risk in individuals with DM, and reducing non-HDL-C has been recommended as an alternative treatment target. 5 However, a high percentage of patients with DM fail to achieve adequate control of LDL-C or non-HDL-C levels with existing lipid-lowering therapies and therefore remain at high risk of ASCVD.
Alirocumab is a fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9). In the ODYSSEY Phase 3 clinical trial program, comprising a comprehensive evaluation of alirocumab in patients with dyslipidaemia and increased ASCVD risk (including 31.0% with DM, n = 223), alirocumab was associated with average reductions in LDL-C of 49% with alirocumab 75 mg/150 mg every 2 weeks (Q2W; 75 mg/150 mg denotes that the initial dose of 75 mg Q2W was increased to 150 mg Q2W at Week 12 depending on Week 8 LDL-C), and 61% with alirocumab 150 mg Q2W. 6, 7 In the 104-week, Phase 3 ODYSSEY COMBO II trial (n = 720), as previously reported, alirocumab 75 mg/150 mg Q2W significantly reduced LDL-C vs ezetimibe in high risk cardiovascular patients receiving background maximally tolerated statin. Mean AE SE reductions in LDL-C from baseline at Week 24 were 50.6% AE 1.4%
for alirocumab vs 20.7% AE 1.9% for ezetimibe (P < .0001). 8 Approximately one third of patients in COMBO II had DM at baseline (n = 225) and 24-week data revealed similar reductions in LDL-C in patients with or without DM. 8 The purpose of this sub-analysis was to investigate in greater detail whether the efficacy and safety of alirocumab, administered to patients receiving maximally tolerated statin, differs between those with DM and those without DM over the long term, using data from the COMBO II study.
| METHODS
The double-blind COMBO II study (clinicaltrials.gov identifier:
NCT01644188) enrolled patients with documented ASCVD and baseline LDL-C ≥70 mg/dL (1.8 mmol/L) and patients without documented ASCVD but with other risk factors and LDL-C ≥100 mg/dL (2.6 mmol/L). All patients in the study were defined as being at high cardiovascular risk. ASCVD was defined as the presence of coronary heart disease (CHD), peripheral artery disease (PAD) or ischaemic 
| Patients

| Endpoints
The present analysis compared alirocumab efficacy and safety in high risk cardiovascular patients with or without DM over a period of 104 weeks, 8, 9 and was a sub-analysis of the COMBO II study. The primary efficacy endpoint was pre-specified, while the secondary endpoints and safety assessments were post-hoc analyses. The primary efficacy endpoint was the percent change in calculated LDL-C from baseline to Week 24, analysed using an intent-to-treat (ITT) approach including all lipid data, whether patients were on or off
treatment. An on-treatment analysis using lipid data collected during the treatment period was also conducted with all patients who 
| Statistical analyses
Efficacy endpoints were analysed using a mixed effect model with a repeated measures approach to account for missing data for all lipid parameters, except Lp(a) and TGs and achievement of LDL-C goals, which were analysed using a multiple imputation approach for handling of missing values, followed by robust regression, and achievement of LDL-C goals, which was analysed using a multiple imputation approach for handling of missing values, followed by logistic regression. The significance level of the treatment-by-DM subgroup factor interaction term at Week 24 was also derived from the mixed effect model with repeated measures. Safety data were analysed using descriptive statistics. Analyses were performed using SAS version 9.2 software (SAS Institute Inc., Cary, North Carolina).
| RESULTS
Overall, 720 patients were randomized, including 225 (31%) patients with DM and 495 (69%) without DM. DM patients were evenly distributed in the alirocumab (n = 148; 31%) and ezetimibe arms (n = 77; 32%). Across the treatment and DM subgroups, the mean age was 60.4 to 63.2 years and mean body mass index ranged from 29.2 to 32.5 kg/m 2 ( Table 1) . Baseline levels of lipids, including LDL-C, non-HDL-C, apo B, Lp(a) and HDL-C, were similar between the alirocumab and ezetimibe groups within the DM and non-DM subgroups ( 
| Efficacy
At Week 24, LDL-C levels were reduced from baseline by 49.1%
and 51.2% in alirocumab-treated patients with or without DM, respectively, vs 18.4% and 21.8% in ezetimibe groups, respectively (P = .8052 for treatment by DM interaction; Figure 1A) . A similar beneficial effect of alirocumab vs ezetimibe was also evident at the 12-week assessment in both groups, with or without DM ( Figure 1A) . Moreover, LDL-C reductions with alirocumab treatment were maintained over 104 weeks in those with or without DM ( Figure 1B) .
At Week 12, 80% of patients with DM and 82% of patients without DM were able to achieve LDL-C levels ≤70 mg/dL (1.8 mmol/L) on alirocumab 75 mg Q2W (ie, without requiring dose increase to 150 mg Q2W). At Week 24, LDL-C target levels ≤70 mg/ dL (1.8 mmol/L) were achieved by 77.9% of alirocumab-treated patients with DM and 77.3% of those without DM, compared with 50.1% and 45.1%, respectively, of ezetimibe-treated patients. This pattern was not seen in the ezetimibe groups; however, the number of ezetimibe-treated patients who received placebo injections and reported injection-site reactions was low (3 patients overall).
A possible limitation of this analysis is that, at randomization, patients were stratified according to history of myocardial infarction Findings from this subanalysis of the COMBO II study are in agreement with subanalyses from other ODYSSEY studies, showing no differences in efficacy between patients with or without DM. 6, 10 Furthermore, a pooled analysis of 10 ODYSSEY trials (including the COMBO II study) did not reveal an increase in new-onset diabetes or adverse changes in glycaemic parameters with alirocumab treatment. 11 A recently published study of the effects of the PCSK9 inhibitor evolocumab in patients with DM also found consistent reductions in atherogenic lipoproteins that were similar in patients with or without DM over the 12 weeks of treatment. 12 Our study, which assessed the effect of alirocumab for up to 104 weeks, indicates that the impact of alirocumab on lipid parameters is maintained over the long term in patients with or without DM.
To conclude, in the longest completed randomized double-blind controlled trial evaluating a PCSK9 inhibitor to date, alirocumab provided clinically relevant greater reductions in LDL-C in patients with DM than those obtained with ezetimibe, with a similar safety profile.
These reductions were maintained over the 104-week duration of the study and were comparable in patients without DM. In addition, treatment with alirocumab enabled more patients, with or without DM, to achieve LDL-C goals as compared with ezetimibe, with a 75 mg Q2W alirocumab dose sufficient for the majority of patients to attain their risk-based LDL-C goal. Further specific studies of the efficacy and safety of alirocumab in patients with DM are currently ongoing (NCT02642159, NCT02585778) and treatment with alirocumab for potential reduction of cardiovascular events is being evaluated in the large ongoing ODYSSEY OUTCOMES study (NCT01663402) which includes a substantial proportion of patients with DM. 13 
